RITE AID CORPORATION AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
For the Years Ended February 27, 2016, February 28, 2015 and March 1, 2014
(In thousands, except per share amounts)
2. Acquisition (Continued)
principal amount of 6.125% senior notes due 2023 (the “6.125% Notes”). The consideration associated
with the common stock was $240,907 based on a stock price of $8.68 per share, representing the closing
price of the Company’s common stock on the closing date of the Acquisition. The closing balance sheet
has not yet been finalized, as the Company is still in process of finalizing the valuation, and therefore,
the final purchase price and related purchase price allocation of the Acquisition is subject to change.
The Company’s consolidated financial statements for fiscal 2016 includes EnvisionRX results of
operations from the Acquisition date of June 24, 2015 through February 27, 2016 (please see Note 20
Segment Reporting for the Pharmacy Services segment results included within the consolidated
financial statements for the fifty-two week period ended February 27, 2016, which reﬂects the results of
EnvisionRX). The Company’s financial statements reﬂect preliminary purchase accounting adjustments
in accordance with ASC 805 “Business Combinations”, whereby the purchase price was preliminarily
allocated to the assets acquired and liabilities assumed based upon their estimated fair values on the
Acquisition date.
The following allocation of the purchase price and the estimated transaction costs is preliminary
and is based on information available to the Company’s management at the time the consolidated
98